Pitolisant
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Pitolisant |
| DrugBank ID | DB11642 |
| Brand Names (EU) | Wakix |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.71% |
Approved Indication (EMA)
Wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | insomnia (disease) | 99.71% | DL |
| 2 | attention deficit-hyperactivity disorder | 99.36% | DL |
| 3 | faciodigitogenital syndrome | 99.29% | DL |
| 4 | X-linked adrenoleukodystrophy | 99.03% | DL |
| 5 | disorder of peroxisomal alpha-, beta- and omega-oxidation | 98.87% | DL |
| 6 | ACBD5 deficiency | 98.65% | DL |
| 7 | Creutzfeldt-Jakob disease | 98.55% | DL |
| 8 | narcolepsy-cataplexy syndrome | 98.49% | DL |
| 9 | narcolepsy | 98.42% | DL |
| 10 | narcolepsy, susceptibility to | 98.21% | DL |
| 11 | megaconial type congenital muscular dystrophy | 97.64% | DL |
| 12 | hypersomnia (disease) | 96.98% | DL |
| 13 | Balo concentric sclerosis | 96.90% | DL |
| 14 | circadian rhythm sleep disorder | 96.73% | DL |
| 15 | chondromyxoid fibroma | 96.61% | DL |
| 16 | narcolepsy without cataplexy | 94.96% | DL |
| 17 | variably protease-sensitive prionopathy | 94.78% | DL |
| 18 | central nervous system disease | 94.77% | DL |
| 19 | attention deficit hyperactivity disorder, inattentive type | 94.48% | DL |
| 20 | Wernicke-Korsakoff syndrome | 93.65% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.